These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 994969)

  • 41. Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
    Jonderko K; Kucio C; Skrzypek D
    Eur J Clin Nutr; 1988 Jul; 42(7):627-31. PubMed ID: 3066620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of mazindol on carbohydrate and insulin metabolism in obesity.
    Harrison LC; King-Roach AP; Sandy KC
    Metabolism; 1975 Dec; 24(12):1353-65. PubMed ID: 1196130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drug therapy in obesity].
    Ishii J
    Nihon Rinsho; 1988 Nov; 46(11):2491-6. PubMed ID: 3241376
    [No Abstract]   [Full Text] [Related]  

  • 45. Mazindol for nocturnal enuresis.
    Tiptaft RC; Woodhouse CR; Badenoch DF
    Br J Urol; 1984 Dec; 56(6):641-3. PubMed ID: 6534482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
    Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
    Inoue S; Egawa M; Satoh S; Saito M; Suzuki H; Kumahara Y; Abe M; Kumagai A; Goto Y; Shizume K
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):199S-202S. PubMed ID: 1728834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mazindol in the treatment of simple obesity].
    Siciński A; Stasiakowa L
    Pol Arch Med Wewn; 1976 Jun; 55(6):581-7. PubMed ID: 781631
    [No Abstract]   [Full Text] [Related]  

  • 49. [Evaluation of the effect of mazindol on the motor function of the stomach in obese persons].
    Kucio C; Jonderko K; Skrzypek D
    Pol Arch Med Wewn; 1988 Apr; 79(4):195-9. PubMed ID: 3270813
    [No Abstract]   [Full Text] [Related]  

  • 50. Amphetamine, mazindol, and fencamfamin in narcolepsy.
    Shindler J; Schachter M; Brincat S; Parkes JD
    Br Med J (Clin Res Ed); 1985 Apr; 290(6476):1167-70. PubMed ID: 2859077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mazindol in Duchenne muscular dystrophy.
    Coakley JH; Edwards RH; Moorcraft J; Hipkin LJ; Smith CS
    Lancet; 1988 Jan; 1(8578):184. PubMed ID: 2893022
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evaluation of the effect of mazindol on the metabolism and lipolysis in obese women].
    Kucio C; Zahorska-Markiewicz B; Piskorska D; Semenowicz-Siuda K; Waluga M
    Pol Arch Med Wewn; 1987 Mar; 77(3):73-6. PubMed ID: 3275392
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy.
    Nishikawa T; Iizuka T; Omura M; Kuramoto N; Miki T; Ito H; Chiba S
    Endocr J; 1996 Dec; 43(6):671-7. PubMed ID: 9075607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effect of mazindol (teronac) on various hormonal indicators in children with simple obesity].
    Komorowski JM; Zwaigzne-Raczyńska J; Owczarczyk I; Gołebiowska M; Zarzycki J
    Pediatr Pol; 1982 Apr; 57(4):241-6. PubMed ID: 6755371
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of simple obesity with mazindol under sanatorium conditions].
    Hasik J; Gawlak E; Tycowa M
    Pol Tyg Lek; 1980 Nov; 35(45):1729-31. PubMed ID: 7012806
    [No Abstract]   [Full Text] [Related]  

  • 56. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of an anorectic agent, AN 448 on weight reduction and plasma lipids.
    Ishikawa T; Nakaya N; Nakamura H; Goto Y
    Keio J Med; 1975 Jul; 24(3):211-8. PubMed ID: 1219154
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of obesity with mazindol (author's transl)].
    Escher M
    Schweiz Rundsch Med Prax; 1976 Jun; 65(24):751-4. PubMed ID: 981189
    [No Abstract]   [Full Text] [Related]  

  • 59. [Use of mazindol in the dietetic treatment of obesity in patients with essential hypertension].
    Kocemba J; Kawecka-Jaszcz K
    Pol Arch Med Wewn; 1978 Dec; 60(6):517-23. PubMed ID: 366579
    [No Abstract]   [Full Text] [Related]  

  • 60. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.